GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Seagen Inc (NAS:SGEN) » Definitions » Cyclically Adjusted PB Ratio

Seagen (Seagen) Cyclically Adjusted PB Ratio : 22.23 (As of May. 27, 2024)


View and export this data going back to 2001. Start your Free Trial

What is Seagen Cyclically Adjusted PB Ratio?

As of today (2024-05-27), Seagen's current share price is $228.74. Seagen's Cyclically Adjusted Book per Share for the quarter that ended in Sep. 2023 was $10.29. Seagen's Cyclically Adjusted PB Ratio for today is 22.23.

The historical rank and industry rank for Seagen's Cyclically Adjusted PB Ratio or its related term are showing as below:

SGEN' s Cyclically Adjusted PB Ratio Range Over the Past 10 Years
Min: 16.07   Med: 18.52   Max: 19.91
Current: 18.52

During the past years, Seagen's highest Cyclically Adjusted PB Ratio was 19.91. The lowest was 16.07. And the median was 18.52.

SGEN's Cyclically Adjusted PB Ratio is not ranked
in the Biotechnology industry.
Industry Median: 1.73 vs SGEN: 18.52

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted book value per share of a company over the past 10 years.

Seagen's adjusted book value per share data for the three months ended in Sep. 2023 was $13.521. Add all the adjusted book value per share for the past 10 years together and divide the count will get our Cyclically Adjusted Book per Share, which is $10.29 for the trailing ten years ended in Sep. 2023.

Shiller PE for Stocks: The True Measure of Stock Valuation


Seagen Cyclically Adjusted PB Ratio Historical Data

The historical data trend for Seagen's Cyclically Adjusted PB Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Seagen Cyclically Adjusted PB Ratio Chart

Seagen Annual Data
Trend Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22
Cyclically Adjusted PB Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - 16.87

Seagen Quarterly Data
Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23
Cyclically Adjusted PB Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 17.52 16.87 16.07 19.17 18.52

Competitive Comparison of Seagen's Cyclically Adjusted PB Ratio

For the Biotechnology subindustry, Seagen's Cyclically Adjusted PB Ratio, along with its competitors' market caps and Cyclically Adjusted PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Seagen's Cyclically Adjusted PB Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Seagen's Cyclically Adjusted PB Ratio distribution charts can be found below:

* The bar in red indicates where Seagen's Cyclically Adjusted PB Ratio falls into.



Seagen Cyclically Adjusted PB Ratio Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted PB Ratio takes the Book Value per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/B calculation. Because it considers this 10-year average, it's often referred to as the CAPB Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio.

Seagen's Cyclically Adjusted PB Ratio for today is calculated as

Cyclically Adjusted PB Ratio=Share Price/ Cyclically Adjusted Book per Share
=228.74/10.29
=22.23

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Seagen's Cyclically Adjusted Book per Share for the quarter that ended in Sep. 2023 is calculated as:

For example, Seagen's adjusted Book Value per Share data for the three months ended in Sep. 2023 was:

Adj_Book=Book Value per Share/CPI of Sep. 2023 (Change)*Current CPI (Sep. 2023)
=13.521/129.8595*129.8595
=13.521

Current CPI (Sep. 2023) = 129.8595.

Seagen Quarterly Data

Book Value per Share CPI Adj_Book
201312 1.877 98.326 2.479
201403 1.876 99.695 2.444
201406 1.831 100.560 2.364
201409 1.818 100.428 2.351
201412 1.701 99.070 2.230
201503 1.677 99.621 2.186
201506 1.433 100.684 1.848
201509 4.992 100.392 6.457
201512 4.911 99.792 6.391
201603 4.883 100.470 6.311
201606 4.759 101.688 6.077
201609 4.680 101.861 5.966
201612 4.459 101.863 5.685
201703 4.230 102.862 5.340
201706 4.011 103.349 5.040
201709 4.588 104.136 5.721
201712 4.692 104.011 5.858
201803 8.088 105.290 9.975
201806 8.714 106.317 10.644
201809 8.525 106.507 10.394
201812 7.949 105.998 9.738
201903 8.151 107.251 9.869
201906 7.868 108.070 9.454
201909 10.400 108.329 12.467
201912 10.909 108.420 13.066
202003 10.227 108.902 12.195
202006 10.434 108.767 12.457
202009 12.889 109.815 15.242
202012 19.282 109.897 22.785
202103 18.887 111.754 21.947
202106 18.647 114.631 21.124
202109 17.314 115.734 19.427
202112 16.715 117.630 18.453
202203 16.306 121.301 17.456
202206 15.907 125.017 16.523
202209 15.234 125.227 15.798
202212 15.029 125.222 15.586
202303 14.540 127.348 14.827
202306 13.956 128.729 14.079
202309 13.521 129.860 13.521

Add all the adjusted book value per share together and divide the count will get our Cyclically Adjusted Book per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Seagen  (NAS:SGEN) Cyclically Adjusted PB Ratio Explanation

Compared with the regular PB Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PB Ratio smoothed out the fluctuations of book value during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted PB Ratio should give similar results to regular PB Ratio.


Seagen Cyclically Adjusted PB Ratio Related Terms

Thank you for viewing the detailed overview of Seagen's Cyclically Adjusted PB Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Seagen (Seagen) Business Description

Industry
Traded in Other Exchanges
N/A
Address
21823 - 30th Drive South East, Bothell, WA, USA, 98021
Seagen (formerly known as Seattle Genetics) is a biotech firm that develops and commercializes therapies to treat cancers. Seagen's therapies are based on antibody-drug conjugate technology that utilizes the targeting ability of monoclonal antibodies to deliver cell-killing agents directly to cancer cells. The company's lead product, Adcetris, has received approval for six indications to treat Hodgkin lymphoma and T-cell lymphoma. Other approved products include Padcev for bladder cancer, Tukysa for breast cancer, and Tivdak for cervical cancer. The company has several other oncology programs in pivotal trials. Seagen also licenses its antibody-drug conjugate technology to several leading biotechnology and pharmaceutical companies.
Executives
David R Epstein director, officer: Chief Executive Officer INTERNATIONAL FLAVORS & FRAGRANCES INC., 521 W. 57TH STREET, NEW YORK NY 10019
Vaughn B Himes officer: See Remarks C/O SEATTLE GENETICS, INC., 21823 30TH DRIVE SE, BOTHELL WA 98021
Charles R Romp officer: EVP, Commercial 21823 30TH DRIVE SE, BOTHELL WA 98021
Roger D Dansey officer: See Remarks 21823 30TH DRIVE SE, BOTHELL WA 98021
Jean I Liu officer: GC & EVP, Legal Affairs 21823 30TH DRIVE SE, BOTHELL WA 98021
Todd E Simpson officer: Chief Financial Officer
Daniel G Welch director 4611 UNIVERSITY DR, 4 UNIVERSITY PLACE, DURHAM NC 27707
David W Gryska director 749 N MARY AVE, SUNNYVALE CA 94085
Sandra M Swain director 21823 30TH DRIVE SE, BOTHELL WA 98021
Ted W Love director C/O GLOBAL BLOOD THERAPEUTICS, INC., 400 EAST JAMIE COURT, SUITE 101, SOUTH SAN FRANCISCO CA 94080
Clay B Siegall director, officer: President and CEO 21823 30TH DR SE, BOTHELL WA 98021
Baker Bros. Advisors Lp director, 10 percent owner 860 WASHINGTON STREET, 3RD FLOOR, NEW YORK NY 10014
Felix Baker director, 10 percent owner BAKER BROS. ADVISORS LP, 860 WASHINGTON STREET 3RD FLOOR, NEW YORK NY 10014
Julian Baker director, 10 percent owner BAKER BROS. ADVISORS LP, 860 WASHINGTON STREET 3RD FLOOR, NEW YORK NY 10014
Baker Brothers Life Sciences Lp director, 10 percent owner 860 WASHINGTON STREET, 3RD FLOOR, NEW YORK NY 10014

Seagen (Seagen) Headlines

From GuruFocus